Given the irreversible beta-cell damage observed in most patients at clinical T1D diagnosis, the study has redefined the therapeutic goal as “preservation of beta-cell function” rather than “complete insulin discontinuation,” driving a paradigm shift from “cure-oriented” to “functional preservation-oriented” approaches. The gene discussed is INS; the disease is type 1 diabetes mellitus.